; increased by (ii) the percentage by which the rebate period CPI–U (as defined in subparagraph (G) for the rebate period exceeds the benchmark period CPI–U (as defined in subparagraph (F)). (D) Rebate period For purposes of this subsection, subject to paragraph (5)(E), the term rebate period means, with respect to a calendar quarter, the period that is 2 calendar quarters prior to such calendar quarter. (E) ASP benchmark quarter The term ASP benchmark quarter means the calendar quarter beginning January 1, 2016. (F) Benchmark period CPI–U The term benchmark period CPI–U means the consumer price index for all urban consumers (United States city average) for January 2016. (G) Rebate period CPI–U The term rebate period CPI–U means, with respect to a rebate period, the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to the rebate period. (5) Special treatment of certain drugs (A) Subsequently approved drugs Subject to subparagraph (B), in the case of a single source rebatable drug first approved by the Food and Drug Administration after January 1, 2016, clause (i) of paragraph (4)(C) shall be applied as if the term ASP benchmark quarter were defined under paragraph (4)(E) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (4)(C) shall be applied as if the term benchmark period CPI–U were defined under paragraph (4)(F) as if the reference to January 2016 under such paragraph were a reference to the first month of the third full calendar quarter after the day on which the drug was first marketed . (B) Special rule for new drugs In applying this subsection in the case of a newly approved single source rebatable drug for which a payment and billing code has not previously been established the first calendar quarter to which this subsection shall apply shall be the sixth full calendar quarter after the day on which the drug was first marketed. (6)